Boston, MA 05/29/2013 (wallstreetpr) – Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) involved in the development of bio technology products for delivering oxygen to tissue had been witnessing decline in the share prices. The shares of the company declined by 12.95 percent to close at $3.90 per share for last trading session. The shares of Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) had been trading in the range of $3.90 to $4.30 per share during the day.
Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) had recently appointed Dr. Charles L. Pamplin III as the chief medical officer who will further be responsible for strategic clinical development plan of the company. The bio pharmaceutical company is involved in the development of Oxycyte, a systemic perfluorcarbon product.
Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) had recently announced a reverse stock split to its shareholders at the ratio of twenty to one after proper approval from the company’s shareholders and the board of directors on April 26, 2013. The company had till now developed a family of perfluorocarbon-based oxygen carriers for use in personal care, topical wound healing, and other topical indications.
The shares of Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) had recorded 52 week low price level of $3.6 per share and 52 week high price level of $45 per share. The company presently holds 2.66 million shares outstanding and the institutional ownership of 5 percent of the holdings. The shares of Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) had witnessed heavy trading volume at 33,046 shares for the last trading session while the average trading volume for the company is only 4,094 shares per day.
